Immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

Immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy. - Immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013251

Enrollment

Registered

2014-02-24

Start date

2008-08-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric soft tissue malignancy and neuroblastoma

Interventions

The patient is intradermally injected with 0.5-3 mg of the HLA-A*2402-restricted, 9-mer modified WT1 peptide (p235-243:CYTWNQMNL) emulsified with Montanide ISA51 adjuvant. The WT1 vaccination is sched

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Metastatic or recurrent rhabdomyosarcoma, Osteosarcoma, Ewing sarcoma, and Neuroblastoma. HLA A2402 WT1 pathologically positive CTC-AE grade 1

Exclusion criteria

Exclusion criteria: 1) active infectious diseases 2) Severe Complications, including Heart failure, Renal faiure, Hapatic failure, ileus, uncontrolable DM, and so on 3) Other severe problems unsuitable for this study active infectious diseases

Design outcomes

Primary

Measure	Time frame
2-year progress free survival rate	—

Secondary

Measure	Time frame
overall survival, safety, 4 -year progress free survival rate	—

Countries

Japan

Contacts

Public ContactYoshiko Hashii

Osaka university graduate school of medicine Pediatrics

areken@ped.med.osaka-u.ac.jp06-6879-3932

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026